PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70
Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG
PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70
Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG
🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS
Proffered paper session 2
#ESMO25 @oncoalert.bsky.social #OncoalertAF
🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS
Proffered paper session 2
#ESMO25 @oncoalert.bsky.social #OncoalertAF
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
youtu.be/CSfTz6Iftek
@realbowtiedoc.bsky.social
@fernandoonco.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@biagioricciutimd.bsky.social
@erikahamilton9.bsky.social
⭐️COMPLETE #ASCO25 EDITION
⭐️REGISTER
👉 oncoalert360.com
👉 buff.ly/48Xpgz0
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@hoperugo.bsky.social
⭐️COMPLETE #ASCO25 EDITION
⭐️REGISTER
👉 oncoalert360.com
👉 buff.ly/48Xpgz0
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@hoperugo.bsky.social
🔗nejm.org/doi/full/10.10…
👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)
@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc
🔗nejm.org/doi/full/10.10…
👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)
@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻
👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%
@oncoalert.bsky.social #OncoAlertAF #ASCO25
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻
👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%
@oncoalert.bsky.social #OncoAlertAF #ASCO25
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
prof @icromeattini.bsky.social 👏🏻👏🏻
✨ Late-Breaking Papers ✨
👉🏻10y FAST-Forward randomised trial
👉🏻 DBCG Skagen trial 1
@oncoalert.bsky.social
prof @icromeattini.bsky.social 👏🏻👏🏻
✨ Late-Breaking Papers ✨
👉🏻10y FAST-Forward randomised trial
👉🏻 DBCG Skagen trial 1
@oncoalert.bsky.social
Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min
You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...
Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min
You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...
mdpi.com/1422-0067/26/8…
👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.socia#OncoAlertAFAF
mdpi.com/1422-0067/26/8…
👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.socia#OncoAlertAFAF
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/l_jcTe69cCs
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/l_jcTe69cCs
www.sciencedirect.com/science/arti...
@oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social
@csabadegi.bsky.social
www.sciencedirect.com/science/arti...
@oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social
@csabadegi.bsky.social
@oncoalert.bsky.social #OncoAlertAF
thegreenjournal.com/article/S0167-…
@oncoalert.bsky.social #OncoAlertAF
thegreenjournal.com/article/S0167-…
A Nonrandomized Clinical Trial
jamanetwork.com/journals/jam...
@oncoalert.bsky.social
A Nonrandomized Clinical Trial
jamanetwork.com/journals/jam...
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
@oncoalert.bsky.social
molecularcancer.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social
molecularcancer.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social
👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭
ro-journal.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social
👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭
ro-journal.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social